Headquartered in Biopole, Epalinges Fiscal year ends December NYSE: ADCT adctherapeutics.com
ADC Therapeutics SA is a commercial-stage biotechnology company specializing in antibody drug conjugates (ADCs) for the treatment of hematological malignancies. Its marketed product, ZYNLONTA (loncastuximab tesirine-lpyl), is a CD19-directed ADC approved under accelerated approval by the FDA and conditional approval by the European Commission for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL). Approximately 5,000 patients have been treated with ZYNLONTA since FDA approval. The company is advancing ZYNLONTA through combination studies, including the LOTIS-7 trial with glofitamab in 2L+ DLBCL and investigator-initiated trials in follicular lymphoma and marginal zone lymphoma. ADC Therapeutics trades on the NYSE under the ticker ADCT and maintains operations in Switzerland and New Jersey. Updated
Biotech dealmaking accelerated heading into the JPM 2026 Healthcare Conference as large drugmakers face looming patent cliffs and hunt for growth. Five therapeutic categories are absorbing most strategic capital: radiopharmaceuticals, next-gen GLP-1,…
Monday's top analyst upgrades and downgrades included Ally Financial, Arbor Realty Trust, Azek, Chesapeake Energy, C3.ai, Endeavor, First Solar, Kingsoft Cloud, Kite Realty, Medtronic and Opendoor Technologies.
Wednesday's top analyst upgrades and downgrades included Allstate, Ally Financial, Five9, General Electric, Host Hotels, Nucor, PayPal, Trade Desk and Zillow.
Tuesday’s top analyst upgrades and downgrades included Campbell Soup, Exact Sciences, Exelixis, Pool, Spirit Airlines and ZTO Express.
These are some of this Monday’s top analyst research summaries of upgrades and downgrades from Wall Street firms: ARM Holdings plc (NASDAQ: ARMH) Cut to Sell at Benchmark. ADC Telecommunications (NASDAQ: ADCT)…
The latest and M&A deal in the world of technology and communications came to ADC Telecommunications Inc. (NASDAQ: ADCT) this week, where Tyco Electronics, Ltd. (NYSE: TEL) is paying $12.75 per share…
These are some of this Wednesday’s top analyst calls with upgrades, downgrades, and initiations seen from Wall Street firms: ADC Telecommunications Inc. (NASDAQ: ADCT) Cut to Hold at Jefferies. Allstate Corp. (NYSE:…
There are many movers today, but a lack of the double-digit gainers and losers we have seen. The movers on news this Thursday for day traders and active traders are ADC Telecommunications…
These are this Monday morning’s top analyst upgrades, downgrades, and initiations seen in early Wall Street research notes: ADC Telecommunications Inc. (NASDAQ: ADCT) Raised to Neutral at JPMorgan. Cisco Systems, Inc. (NASDAQ:…
These are some of the top analyst downgrades we are seeing from Wall Street firms this Thursday morning with more than two hours to the open: ADC Telecommunications (ADCT) Cut to Underweight…
ADC Telecom (NASDAQ: ADCT) is trimming its fiscal revenue guidance and throwing out almost every other bit of key restructuring and financial data to offer some stability to the situation. The telecom…
Douglas A. McIntyre These are some of the top downgrades or negative analyst calls we are seeing this Wednesday morning in early pre-market hours: ADC Telecom (ADCT) Cut to Neutral at Baird; Cut to Market…
These aren’t all of the downgrades or negative analyst calls we have seen this Wednesday, but these are some of the impact analyst calls we are seeing: ADC Telecommunications (NASDAQ: ADCT) Cut…
These are ten of the analyst calls we are focusing on this Friday morning: ADC Telecom (NASDAQ: ADCT) raised to Overweight at JPMorgan. AnnTaylor (NYSE: ANN) raised to Outperform at FBR. Ashland…
These are some of the top analyst calls we are looking at this Wednesday morning: ADC Telecom (NASDAQ: ADCT) raised to Buy from Hold at Jefferies. Alexion Pharma (NASDAQ: ALXN) started as…
ADC Therapeutics SA is a commercial-stage biotechnology company specializing in antibody drug conjugates (ADCs) for the treatment of hematological malignancies.
The Wall Street consensus 12-month price target for ADCT is $3.33.
